Genkyotex : FY 2018 results in line – final phase II results in Q2 (PBC)
>FY 2018 results in line - Genkyotex reported its full-year results this morning. Cash came to € 10.3m end-2018 (already known).Along with this publication, the group provided an update on the clinical trial of GKT831 in primary biliary cholangitis (PBC). The trial is going according to plan. The final results are expected in the spring of this year (90% of the patients have completed the 24 weeks of treatment) while an abstract of the intermediate results should...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.